Page 11 - பல்கலைக்கழகம் ஆஃப் கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் கொலராடோ அண்சச்சுட்ஸ் மருத்துவ வளாகம் Today - Breaking & Trending Today

Why is COVID-19 killing so many young children in Brazil? Doctors are baffled


Why is COVID-19 killing so many young children in Brazil? Doctors are baffled
Firstpost
4 hours ago
The New York Times
© Provided by Firstpost
Why is COVID-19 killing so many young children in Brazil? Doctors are baffled
Rio De Janeiro: Fretting over a fever in her toddler that wouldn’t break, the mother took the young girl, Letícia, to a hospital. Doctors had worrisome news: It was COVID-19.
But they were reassuring, noting that children almost never develop serious symptoms, said the mother, Ariani Roque Marinheiro.
Less than two weeks later, on 27 February, Letícia died in the critical care unit of the hospital in Maringá, in southern Brazil, after days of labored breathing. ....

Rio De Janeiro , Estado Do Rio , United States , Ariani Roque Marinheiro , Ribas Freitas , Lara Shekerdemian , Ricardo Ribas Freitas , Sean Oleary , Luisa Pacheco , Jair Bolsonaro , American Academy Of Pediatric , University Of Colorado Anschutz Medical Campus , Leopoldo Mandic College , Heitor Vieira Dourado Tropical Medicine Foundation , Firstpost Why , Ariani Roque , American Academy , Colorado Anschutz Medical , Texas Children , Pediatric Infectious Disease Journal , Latin America , Ana Luisa Pacheco , President Jair Bolsonaro , ரியோ டி ஜானிரோ , எஸ்டாடோ செய் ரியோ , ஒன்றுபட்டது மாநிலங்களில் ,

Researchers develop new way to evaluate tuberculosis treatments


Researchers develop new way to evaluate tuberculosis treatments
18
May, 2021
Gregory Robertson, an assistant professor in the Department of Microbiology, Immunology and Pathology at CSU, is one of the first authors on the study. He said that the effectiveness of tuberculosis treatments has been judged by studying tissue cultures from infected patients. Photo: John Eisele/CSU Photography
Tuberculosis, a disease caused by the bacterium 
Mycobacterium tuberculosis, is a serious global health threat. The disease caused an estimated 1.5 million deaths in 2019 and current methods often fail to predict treatment outcomes in patients.
Nature Communications provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter treatment regimens. The research team was led by scientists at the University of Colorado Anschutz Medical Campus with Colorado State University’s Mycobacteria R ....

Carol Wilusz , Martin Voskuil , Payam Nahid , Gregory Robertson , Michelle Ramey , Anne Lenaerts , Nicholas Walter , Allison Bauman , Brendan Podell , Nature Communications , Department Of Microbiology , Consortium For Applied Microbial Metrics , University Of California San Francisco Center , University Of Colorado Anschutz Medical Campus , Colorado State University Mycobacteria Research Laboratories , University Of California San Francisco , Colorado Anschutz Medical Campus , Colorado State University , Mycobacteria Research Laboratories , California San , Colorado Anschutz Medical , California San Francisco Center , Applied Microbial Metrics , Victoria Ektnitphong , பயம் நஹித் , கிரெகொரி ராபர்ட்சன் ,

Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization


Share this article
Share this article
RARITAN, N.J., May 16, 2021 /PRNewswire/  The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO
® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO
® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiolo ....

United States , Marcp Bonaca , Jennifer Mcintyre , Lee Pasqualoni , Christopher Delorefice , Jennifer Silvent , American Heart Association , Division Of Cardiovascular Medicine , Janssen Pharmaceuticals Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Journal Of The American College Cardiology , Clinical Research , Department Of Medicine , None Of The Janssen Pharmaceutical Companies , University Of Colorado Anschutz Medical Campus , American College Of Cardiology , Drug Administration , Exchange Commission , Companies Of Johnson , American College , Annual Scientific Session , Cardiovascular Medicine , Colorado Anschutz Medical Campus , Hazard Ratio ,